Literature DB >> 32189327

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update.

C H Smith1, Z Z N Yiu2, T Bale3, A D Burden4, L C Coates5,6, W Edwards7, E MacMahon8, S K Mahil1, A McGuire9, R Murphy10,11,12, C Nelson-Piercy13, C M Owen14, R Parslew15, O A Uthman16, R T Woolf1, L Manounah17, M C Ezejimofor17, L S Exton17, M F Mohd Mustapa17.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32189327     DOI： 10.1111/bjd.19039

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  24 in total

Review 1.  Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.

Authors:  Tung-Lin Lee; Tsen-Fang Tsai
Journal:  Inflamm Res       Date:  2022-01-04       Impact factor: 4.575

Review 2.  Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review.

Authors:  Donovan G Kearns; Shelley Uppal; Vipawee S Chat; Jashin J Wu
Journal:  J Clin Aesthet Dermatol       Date:  2021-06-01

Review 3.  Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases.

Authors:  Ana Ion; Alexandra Maria Dorobanțu; Liliana Gabriela Popa; Mara Mădălina Mihai; Olguța Anca Orzan
Journal:  Biology (Basel)       Date:  2022-05-25

4.  The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis.

Authors:  Lanmei Lin; Yilun Wang; Xiaonian Lu; Tianxiao Wang; Qunyi Li; Runnan Wang; Jinfeng Wu; Jinhua Xu; Juan Du
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

5.  Psoriasis: a brief overview.

Authors:  Antony Raharja; Satveer K Mahil; Jonathan N Barker
Journal:  Clin Med (Lond)       Date:  2021-05       Impact factor: 2.659

Review 6.  Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2020-08       Impact factor: 9.546

7.  The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA.

Authors:  Ioana Gherghescu; M Begoña Delgado-Charro
Journal:  Pharmaceutics       Date:  2020-12-31       Impact factor: 6.321

Review 8.  The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines.

Authors:  Witold Owczarek; Irena Walecka; Aleksandra Lesiak; Rafał Czajkowski; Adam Reich; Iwona Zerda; Joanna Narbutt
Journal:  Postepy Dermatol Alergol       Date:  2021-01-06       Impact factor: 1.837

9.  Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists.

Authors:  Tim Raine; Maria Angeliki Gkini; Peter M Irving; Arvind Kaul; Eleanor Korendowych; Philip Laws; Amy C Foulkes
Journal:  BioDrugs       Date:  2021-02-26       Impact factor: 5.807

10.  COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision.

Authors:  E Sotiriou; K Bakirtzi; I Papadimitriou; E Paschou; E Vakirlis; A Lallas; D Ioannides
Journal:  Br J Dermatol       Date:  2021-04-18       Impact factor: 11.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.